Do analysts rate LNAI or INCR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LNAI or INCR more profitable?

InterCure's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% InterCure N/A N/A N/A

Do analysts recommend TIL or LNAI?

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 778.83%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Lunai Bioworks. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, TIL or LNAI?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Instil Bio N/A N/A -$71.37M -$7.08 N/A Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A

Is TIL or LNAI more profitable?

Instil Bio's return on equity of -39.76% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Instil Bio N/A -39.76% -22.38% Lunai Bioworks N/A -1,243.45% -1,617.76%

Do analysts rate LNAI or INMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is LNAI or INMB more profitable?

INmune Bio's return on equity of -103.03% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% INmune Bio N/A -103.03% -77.66%

Do analysts recommend LNAI or TCRT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, LNAI or TCRT?

Lunai Bioworks is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is LNAI or TCRT more profitable?

Alaunos Therapeutics' return on equity of -165.94% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Alaunos Therapeutics N/A -165.94% -123.50%

Do analysts recommend LNAI or MAAQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lunai Bioworks 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings and valuation, LNAI or MAAQ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lunai Bioworks N/A N/A -$178.01M -$0.40 N/A Mana Capital Acquisition N/A N/A N/A N/A N/A

Is LNAI or MAAQ more profitable?

Mana Capital Acquisition's return on equity of 0.00% beat Lunai Bioworks' return on equity. Company Net Margins Return on Equity Return on Assets Lunai Bioworks N/A -1,243.45% -1,617.76% Mana Capital Acquisition N/A N/A N/A

Lunai Bioworks (LNAI) Competitors

$2.88 -0.10 (-3.36%)

Closing price 07/16/2026 04:00 PM Eastern

Extended Trading

$2.88 +0.00 (+0.17%)

As of 07/16/2026 06:44 PM Eastern

Compare

LNAI vs. INCR, TIL, INMB, TCRT, and MAAQ

Should you buy Lunai Bioworks stock or one of its competitors? MarketBeat compares Lunai Bioworks with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lunai Bioworks include InterCure (INCR), Instil Bio (TIL), INmune Bio (INMB), Alaunos Therapeutics (TCRT), and Mana Capital Acquisition (MAAQ). These companies are all part of the "pharmaceutical products" industry.

How does Lunai Bioworks compare to InterCure?

Lunai Bioworks (NASDAQ:LNAI) and InterCure (NASDAQ:INCR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

InterCure has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
InterCure	$78.47M	0.63	-$10.37M	$0.03	30.10

In the previous week, Lunai Bioworks and Lunai Bioworks both had 2 articles in the media. Lunai Bioworks' average media sentiment score of 1.43 equaled InterCure'saverage media sentiment score.

Company	Overall Sentiment
Lunai Bioworks	Positive
InterCure	Positive

InterCure's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
InterCure	N/A	N/A	N/A

Lunai Bioworks has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market. Comparatively, InterCure has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Comparatively, 0.2% of InterCure shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

InterCure beats Lunai Bioworks on 7 of the 9 factors compared between the two stocks.

How does Lunai Bioworks compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and Lunai Bioworks (NASDAQ:LNAI) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, dividends, profitability, valuation, earnings, risk and institutional ownership.

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 71.4% of Lunai Bioworks shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Instil Bio presently has a consensus price target of $66.00, indicating a potential upside of 778.83%. Given Instil Bio's stronger consensus rating and higher possible upside, equities analysts clearly believe Instil Bio is more favorable than Lunai Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Instil Bio has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market. Comparatively, Lunai Bioworks has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Instil Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A

In the previous week, Instil Bio and Instil Bio both had 2 articles in the media. Instil Bio's average media sentiment score of 1.74 beat Lunai Bioworks' score of 1.43 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Very Positive
Lunai Bioworks	Positive

Instil Bio's return on equity of -39.76% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-39.76%	-22.38%
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%

Summary

Instil Bio beats Lunai Bioworks on 9 of the 11 factors compared between the two stocks.

How does Lunai Bioworks compare to INmune Bio?

Lunai Bioworks (NASDAQ:LNAI) and INmune Bio (NASDAQ:INMB) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

INmune Bio has higher revenue and earnings than Lunai Bioworks. Lunai Bioworks is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
INmune Bio	$50K	1,100.41	-$45.93M	-$1.67	N/A

In the previous week, INmune Bio had 2 more articles in the media than Lunai Bioworks. MarketBeat recorded 4 mentions for INmune Bio and 2 mentions for Lunai Bioworks. Lunai Bioworks' average media sentiment score of 1.43 beat INmune Bio's score of 0.29 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
INmune Bio	Neutral

INmune Bio's return on equity of -103.03% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
INmune Bio	N/A	-103.03%	-77.66%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

71.4% of Lunai Bioworks shares are owned by institutional investors. Comparatively, 12.7% of INmune Bio shares are owned by institutional investors. 0.5% of Lunai Bioworks shares are owned by company insiders. Comparatively, 21.4% of INmune Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Lunai Bioworks has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Summary

INmune Bio beats Lunai Bioworks on 10 of the 13 factors compared between the two stocks.

How does Lunai Bioworks compare to Alaunos Therapeutics?

Lunai Bioworks (NASDAQ:LNAI) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, analyst recommendations, earnings, dividends, risk, institutional ownership, media sentiment and valuation.

In the previous week, Lunai Bioworks had 1 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 2 mentions for Lunai Bioworks and 1 mentions for Alaunos Therapeutics. Alaunos Therapeutics' average media sentiment score of 1.87 beat Lunai Bioworks' score of 1.43 indicating that Alaunos Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Alaunos Therapeutics	Very Positive

Alaunos Therapeutics' return on equity of -165.94% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Lunai Bioworks is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Lunai Bioworks has a beta of 0.37, indicating that its share price is 63% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, indicating that its share price is 202% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Alaunos Therapeutics beats Lunai Bioworks on 6 of the 10 factors compared between the two stocks.

How does Lunai Bioworks compare to Mana Capital Acquisition?

Lunai Bioworks (NASDAQ:LNAI) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lunai Bioworks	N/A	N/A	-$178.01M	-$0.40	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

In the previous week, Lunai Bioworks had 2 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 2 mentions for Lunai Bioworks and 0 mentions for Mana Capital Acquisition. Lunai Bioworks' average media sentiment score of 1.43 beat Mana Capital Acquisition's score of 0.00 indicating that Lunai Bioworks is being referred to more favorably in the media.

Company	Overall Sentiment
Lunai Bioworks	Positive
Mana Capital Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lunai Bioworks	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mana Capital Acquisition's return on equity of 0.00% beat Lunai Bioworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lunai Bioworks	N/A	-1,243.45%	-1,617.76%
Mana Capital Acquisition	N/A	N/A	N/A

71.4% of Lunai Bioworks shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 0.5% of Lunai Bioworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Lunai Bioworks beats Mana Capital Acquisition on 5 of the 7 factors compared between the two stocks.

Get Lunai Bioworks News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LNAI vs. The Competition

Export

Metric	Lunai Bioworks	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$13.51M	$942.35M	$5.09B	$12.67B
Dividend Yield	N/A	4.84%	34.29%	8.87%
P/E Ratio	-7.20	1.53	23.66	24.05
Price / Sales	N/A	113.16	132.64	112.08
Price / Cash	N/A	20.06	164.96	59.89
Price / Book	-0.29	8.62	11.84	6.23
Net Income	-$178.01M	-$3.23M	$121.47M	$331.94M
7 Day Performance	-2.04%	-2.90%	-2.03%	-1.65%
1 Month Performance	-28.00%	-1.52%	-2.94%	-1.03%
1 Year Performance	N/A	36.63%	9.82%	17.10%

Lunai Bioworks Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LNAI Lunai Bioworks	0.8999 of 5 stars	$2.88 -3.4%	N/A	N/A	$13.51M	N/A	N/A	20	Positive News Short Interest Decrease Gap Down
INCR InterCure	1.356 of 5 stars	$0.97 -1.0%	N/A	-39.8%	$53.04M	$78.47M	32.33	350	Positive News
TIL Instil Bio	1.8206 of 5 stars	$7.70 +0.5%	$66.00 +757.1%	-70.8%	$52.22M	N/A	N/A	410	News Coverage
INMB INmune Bio	0.9149 of 5 stars	$1.94 +8.4%	N/A	-11.5%	$51.57M	$50K	N/A	10	News Coverage
TCRT Alaunos Therapeutics	0.5848 of 5 stars	$2.05 -1.0%	N/A	-36.3%	$50.07M	N/A	N/A	40	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LNAI) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lunai Bioworks (LNAI) Competitors

LNAI vs. INCR, TIL, INMB, TCRT, and MAAQ

How does Lunai Bioworks compare to InterCure?

Summary

How does Lunai Bioworks compare to Instil Bio?

Summary

How does Lunai Bioworks compare to INmune Bio?

Summary

How does Lunai Bioworks compare to Alaunos Therapeutics?

Summary

How does Lunai Bioworks compare to Mana Capital Acquisition?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lunai Bioworks (LNAI) Competitors

LNAI vs. INCR, TIL, INMB, TCRT, and MAAQ

How does Lunai Bioworks compare to InterCure?

Do analysts rate LNAI or INCR?

Which has stronger valuation and earnings, LNAI or INCR?

Does the media prefer LNAI or INCR?

Is LNAI or INCR more profitable?

Which has more risk & volatility, LNAI or INCR?

Do insiders & institutionals believe in LNAI or INCR?

Summary

How does Lunai Bioworks compare to Instil Bio?

Do insiders and institutionals have more ownership in TIL or LNAI?

Do analysts recommend TIL or LNAI?

Which has more volatility and risk, TIL or LNAI?

Which has higher earnings and valuation, TIL or LNAI?

Does the media favor TIL or LNAI?

Is TIL or LNAI more profitable?

Summary

How does Lunai Bioworks compare to INmune Bio?

Which has better valuation and earnings, LNAI or INMB?

Does the media refer more to LNAI or INMB?

Is LNAI or INMB more profitable?

Do analysts rate LNAI or INMB?

Do institutionals and insiders have more ownership in LNAI or INMB?

Which has more risk & volatility, LNAI or INMB?

Summary

How does Lunai Bioworks compare to Alaunos Therapeutics?

Does the media refer more to LNAI or TCRT?

Is LNAI or TCRT more profitable?

Do insiders & institutionals have more ownership in LNAI or TCRT?

Which has preferable valuation & earnings, LNAI or TCRT?

Which has more risk and volatility, LNAI or TCRT?

Do analysts recommend LNAI or TCRT?

Summary

How does Lunai Bioworks compare to Mana Capital Acquisition?

Which has better earnings and valuation, LNAI or MAAQ?

Does the media favor LNAI or MAAQ?

Do analysts recommend LNAI or MAAQ?

Is LNAI or MAAQ more profitable?

Do institutionals and insiders have more ownership in LNAI or MAAQ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LNAI vs. The Competition

Lunai Bioworks Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools